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Summary: The effects of carcinogenic heterocyclic amines and -carbolines on 5-hydroxytryptamine-induced
human platelet aggregation,-on the uptake of 5-hydroxytryptamine by platelets, and on human monoamine
oxidase activity were investigated. Of the dietary carcinogens and -carbolines studied, carcinogenic tryptophan
pyrolysis products had greater pharmacological activities than other heterocyclic amines. The carcinogenic
tryptophan pyrolysis products, 3-amino-l,4-dimethyl-5H-pyrido[4,3-b]indole and 3-amino-l-methyl-5H-pyr-
ido[4,3-b]indole, which have been identified in the dialysis fluid of uraemic patients, were the most potent
inhibitors of the aggregation response to 5-hydroxytryptamine, with IC50 (the concentrations causing 50%
inhibition) values of 10 μιηοΐ/ΐ and 50 μιηοΐ/ΐ, respectively. 3-Amino-l,4-dimethyl-5H-pyrido[4,3-b]indoleand
3-amino-l-methyl-5H-pyrido[4,3-b]indole by themselves did not induce platelet aggregation, although these
dietary carcinogens structurally resemble 54iydroxytryptamine. Kinetic analyses showed that 3-amino-l,4-
dimethyl-5H-pyrido[4,3^b]indole and 3*amino-l-methyl-5H-pyrido[4,3-b]indole were potent competitive inhib-
itors of 5-hydroxytryptamine uptake by platelets with /ζ 18 μπιοΐ/ΐ and 42 μιηοΐ/ΐ, respectively. Furthermore,
carcinogenic tryptophan pyrolysates as well as -carbolines were found to be competitive selective inhibitors
of monoamine oxidase 'type A'.
Introduction Among such carcinogens, 3-amino-l ,4-dimethyl-5H-
During the last decade, a new series of heterocyclic pyrido[4,3-b]indole, 3-amino-l-methyl-5H-pyr-
amines has been isolated as potent mutagens from ido[4,3-b]indole and γ-carboline derivatives, strongly
pyrolysates of amino acids and proteins and from inhibit human platelet aggregation by inhibiting pros-
broiled fish and meat (1, 2). All the mutagenic het- taglandin endoperoxide synthetase (7). In the course
erocyclic amines so far tested have been shown to be of the previous study, we found that 3-amino-l,4-
carcinogenic in experimental animals (1,2). Recently, dimethyl-5H-pyrido[4,3-b]indole and 3-amino-l -
some mutagenic and carcinogenic heterocyclic amines methyl-5H-pyrido[4,3-b]indole are also potent inhib-
such as 3,amino-l,4-dimethyl-5H-pyrido[4,3-b]indole, itors of 5-hydroxytryptamine-induced human platelet
3-amino-l-methyl,5H-pyrido[4,3-b]indole, 2-amino- aggregation. Since aggregation induced by 5-hydroxy-
o-methyldipyridoIl^-arS'^'-dlimidazole and 2-ami- tryptamine is mediated by a specific receptor (8, 9),
nodipyrido[l>a:^2'-d]imidazote were identified in il is perhaps relevant that the tryptophan pyrolysis
the dialysis fluid of patients with uraemia, and in products, 3-amino-l,4-dimethyl-5H-pyrido[4,3-b]-
human plasma (3—6). indole and 3-amino-l -methyl-5H-pyrido[4,3-b]indole,
are structurally related to 5-hydroxytryptamine (ser-
0 Enzyme: Monoamine oxidase (amine: oxygen oxidoreduc- otonm).
tese, deaminating, flavin-containing; E.G. 1.4.3.4)
 On the other hand .carbo nes such as tetrahydro-
*) This research was supported in part by a Grant-m-Aid for
 Λ , ,. , , ^ , , , A- · t -*Scientific Research firom the Ministry of Education, Science -carbohne have been reported to be selective mhib-
and Culture of Japan. itors of monoamine oxidase A (EC 1.4.3.4) (10—12).
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Furthermore, tetrahydro- -carboline and/or its deriv-
atives which structurally resemble 5-hydroxytrypt-
amine were shown to be potent uptake inhibitors of
5-hydroxytryptamine in human platelets and mouse
brain (11, 13). These findings suggested us that 3-
amino-1,4-dimethyl-5H-pyrido[4,3-b]indole and 3-
amino-l-methyl-5H-pyrido[4,3-b]indole may be not
only 5-hydroxytryptamine -uptake inhibitors but also
potent monoamine oxidase inhibitors. In the present
report, we describe the effects of carcinogenic tryp-
tophan pyrolysates on 5-hydroxytryptamine-induced
platelet aggregation, human platelet 5-hydroxytrypt-
amine uptake and human monoamine oxidase activity
in vitro. The chemical structures of the heterocyclic
amines including -carbolines used in the present
study are shown in figure 1.
CH2CH2NH2
CH3
NH
5-Hy droxy t r yp famine
( Serotonin)
3-Amino -1,4- dimethyl -5H-pyrido
[4,3-b] indole
3-Amino-1- methyl -5H-pyrido
[4,3-b] indole
Tetrahydro-p-carboline
Norharman
Harman
Harmine
2-Amino-6-methyldipyrido
[1,2-3:3', 2'- djimidazole
2 -Aminodipyrido
[1,2-a: 3i/2'-d]imidazole
2-Amino-3-methyiimidazo
[4,5-f] quinoline
2-Amino- 3.8 - dimethylimidazo
[4,5-f] quinoxaline
Fig. 1. Chemical structures of carcinogenic heterocyclic amines
and -carbolines used in the present study.
N-CH3
Materials and Methods
Preparation of platelet-rich plasma
Human blood (9 vol) was collected in 1 vol of 38 g/1 trisodium
citrate as an anticoagulant. The citrated blood was gently mixed
and centrifuged at 180# for 20 min at 20 °C, and the super-
natant (platelet-rich plasma) was carefully transferred with a
plastic pipette into plastic tubes. For the preparation of platelet-
poor plasma, the remainder of the blood was centrifuged at
3000 g for 15 min. For platelet aggregation studies, the platelet
concentration of platelet-rich plasma was adjusted to 2—5
χ 10n/l by addition of an appropriate amount of platelet-poor
plasma (14).
Platelet aggregation
This was performed at 37 °C using a Chronolog aggregometer
(Chronolog Co., Havertown, PA, U.S.A.) (7, 14, 15). Aggre-
gation was measured as percent light transmission, using the
light transmission of platelet-rich plasma as 0% and that of
platelet-poor plasma as 100%. Platelet aggregation was initiated
using 5-hydroxytryptamine and ADP. Added chemicals con-
sisted of 10% of the final volume of the assay mixture (14).
Hererocyclic amines were dissolved in saline and added to
platelet-rich plasma just before the addition of the stimulator.
5-Hydroxytryptamine uptake studies
The uptake of [14C]5-hydroxytryptamine into human platelets
was determined by the method of Omen & Smith (16) with the
following modification. Platelet-rich plasma was prepared from
whole blood in sodium citrate instead of using EDTA, and
platelet-rich plasma was diluted with saline instead of platelet-
poor plasma, because the latter contains unknown inhibitors
of 5-hydroxytryptamine uptake (17). The average platelet
counts in all experiments were in the range of 6—8 χ 10n/l
and the specific activity of the [I4C]5-hydroxytryptamine used
was 7200—8400 Bq/pmol. Platelet-rich plasma was incubated
at 37 °C in the small polypropylene centrifuge tubes with raT
dioactive 5^hydroxytryptamine with or without the heterocyclic
amines at different concentrations. The final volume in each
tube was 1 ml. After incubation, the tubes were centrifuged in
the Beckman Microfuge at 20 000 g for 30s. The supernatant
was decanted and the inside of the tube above the platelet pellet
was wiped with cotton-tipped applicators to remove final traces
of plasma. The pellet was resuspended in 200 μΐ water and
frozen and thawed twice to lyse the platelets and to release
their 5-hydroxytryptamine (8). The lysate was transferred into
the vial of a scintillation counter. Each vial received 10 ml
Scintisol EX-Η (Dojindo Laboratories, Kumamoto, Japan) and
radioactivities were estimated by liquid scintillation counting.
The radioactivity of the sample which was incubated at 0 °C
was defined as the non-specific [l4C]5-hydroxytryptamine up-
take. The specific uptake was calculated as total minus non-
specific uptake. Preliminary experiments showed in linear re-
lationship between the incubation time (l min to 20 min) and
the amount of incorporated radioactive 5-hydroxytryptamine.
Therefore, in subsequent experiments, radioactive 5-hydroxy-
tryptamine was incubated with platelet-rich plasma for 5 min.
Sources of monoamine oxidase
Human platelets were used as a source of monoamine oxidase
B and human placenta as a source of monoamine oxidase A
(18, 49). Platelet-rich plasma (20 ml), prepared as described
above, was centrifuged at 3000 g for 10 min. The supernatant
was removed by decantation and the platelet pellets were
washed with 0.32 mol/1 sucrose by suspension and resedirnen-
tation at 3000 g. The pellets were finally resuspended in 2 ml
of 0.32 mol/1 sucrose and finally sonicated with an ultrasonic
disintegrator for 30 s and frozen at -20^0 for future use (20).
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Fresh human placenta (760 g) was washed three times with ice
cold saline. An homogenate of placenta (100 g, made up with
10 mmol/1 phosphate b ffer, pH 7.4 to 1 liter) was prepared
and frozen at -20 °C until use (12). Before the monoamine
oxidase assay, an aliquot was diluted twenty-fold with 100
mmol/1 phosphate buffer at pH 7.4.
Monoamine oxidase assay
The reaction mixture contained 410 μΐ of 50 mmoi/1 phosphate
buffer, pH 7.4, 50 μΐ of heterocyclic amine solution in 50 mmol/1
phosphate buffer, 20 μΐ of monoamine oxidase preparation and
20 μΐ of substrate solution. Controls contained 50 μΐ of phos-
phate buffer in place of the heterocyclic amine solution. [14C]5-
Hydroxytryptamine and [14C]phenylethylamine were diluted
with non-radioactive substrate. Mixtures were incubated for 30
min at 37 °C and the reaction stopped on ice followed by the
addition of 100 μΐ of 2mol/l citric acid (12). The labelled
products of the reaction were extracted into 3 ml of toluene/
ethylacetate (1 + 1, by vol) when 5-hydroxytryptamine was
used as substrate, and into 3 ml of toluene for phenylethylamine
(12). Radioactivities were measured by liquid scintillation
counting. All assays were carried out in duplicate and concen-
trations of heterocyclic amines causing 50% inhibition of [14C]5-
hydroxytryptamine and [14C]phenylethylamine deamination by
monoamine oxidase (IC50) were determined graphically. The
concentrations of [14C]5-hydroxytryptamine and
[14C]phenylethylamine in the incubation medium were 10.4
μηαοΐ/ΐ and 11.4 μηιοΐ/l, respectively.
Materials
5-Hydroxy[side-chain 2-14C]tryptamine-creatinine sulphate
(2.11 TBq/mol = 57.0 mCi/mmol) and 2-phenyl[l-
14C]ethylamine hydrochloride (2.22 TBq/mol = 60.0 mCi/
mmol) were from Amersham International (Amersham, U. K.).
5-Hydroxytryptamine creatinine sulphate complex and -phen-
ylethylamine hydrochloride were from Wako Pure Chemical
Industries (Osaka, Japan). Harman hydrochloride, norharman
and tetrahydro- -carboline were from Sigma Chemical Co. (St.
Louis, MO, U.S.A.). 3-Amino-l,4-dimethyl-5H-pyr-
ido[4,3-b]indole acetate, 3^amino-l-methyl-5H-pyrido[4,3-
b]indole acetate, 2-amino-6-methyldipyrido[l,2^a:3',2'-d] iniida-
zole hydrochloride and 2-aminodipyrido[l,2-a:3',2'-d]imidazole
hydrochloride were from Wako Pure Chemical Industries. 2-
Amino-3-methylimidazo[4,5-f]quinoline hydrochloride and 2-
amino-2,8^dimethylimidazo[4,5rf|quinoxaline hydrochloride
were kindly provided by Dr. Shigeaki Sato, National Cancer
Center Research Institute (Tokyo, Japan). All other chemicals
were of analytical grade.
Results
Effects of heterocyclic amines on human
platelet aggregation
It is well known that 5-hydroxytryptamine induces a
transient reversible platelet aggregation in 90% of a
normal population (8, 21), while the platelet aggre-
gation response to ADP is biphasic and irreversible
at high doses of the stimulant. Aggregation induced
by these stimulants is mediated by specific receptors,
The Km value of the platelet aggregation response to
5-hydroxytryptamine was determined from the initial
rate of aggregation induced by concentrations of 5-
hydroxytryptamine ranging from 1.0 — 20 μηιοΐ/ΐ (11).
5-Hydroxytryptamine
120μπκ>1/Π Inhibitor
lpmol/ l )
10
25
Fig. 2. Inhibitory effects of 3-amino-l,4-dimethyl-5H-pyr-
ido[4,3-b]indole on human platelet aggregation induced
by 5-hydroxytryptamine. The extent of aggregation was
measured as percent light transmission at 610 nm. Pa-
rentheses indicate the final concentrations of the inhib-
itor (μιηοΐ/ΐ).
The determined Km value was 0.38 μηιοΐ/ΐ, which
agrees with the value reported previously (11). As
shown in figure 2, the inhibitory effects of 3-amino-
1,4-dimethyl-5H-pyrido[4,3-b]indole on 5-hydroxy-
Tab. 1. Effects of heterocyclic amines on 5-hydroxy tryptamine-
induced human platelet aggregation
Compounds Km IC50*
(μπιοΐ/ΐ) (μπιοΐ/ΐ)
5-Hydroxytryptamine
Carcinogenic
heterocyclic amines
3-Amino-l ,4-dimethyl-5H-
pyrido[4,3-b]indole
3-Amino-l -methyl-5H-
pyrido[4,3-b]indole
2^Amino-6-methyldipyrido
[l,2-a:3',2'-d]imidazole
2-Amino-dipyrido
[l^-a.^'^'-djimidazole
2-Amino-3-methyl-
imidazo[4,5-fjquinoline
2-Amino-3,8-dimethyI-
imidazo[4,5-f]quinoxaline
-Carbolines
Tetrahydro- -carboline
Norharman
Harman
Harmine
0.38
10
50
150
150
No inhibition
(100)**
No inhibition
(100)**
150
200
200
170
* Concentrations of compounds causing 50% inhibition of
5-hydroxytryptamine (20 μmol/l)-induced platelet aggrega-
tion.
** The maximum concentration (μιηοΐ/ΐ) used for the experi-
ment.
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tryptamine-induced platelet aggregation was dose-de-
pendent. The IC50 (the concentration causing 50%
inhibition) for platelet aggregation induced by 5-hy-
droxytryptamine was estimated graphically. Among
the heterocyclic amines tested in this study, 3-amino-
1,4-dimethyl-5H-pyrido[4,3-b]indole was the most po-
tent inhibitor, with an IC50 of 10 μιηοΐ/ΐ (tab. 1). 3-
Amino-1 -methyl-5H-pyrido[4,3-b]indole, tetrahydro-
-carboline and harmine were less potent inhibitors
than 3-amino-l,4-dimethyl-5H-pyrido[4,3-b]iiidole. 2-
Amino-3-methylimidazo[4,5-f]quinoline and 2-amino-
3,8-dimethylimidazo[4,5-f]quinoxaline did not show
significant effects on 5-hydroxytryptamine-induced
platelet aggregation, even at a concentration of 100
μιηοΐ/ΐ.
Although these heterocyclic amines structurally re-
semble 5-hydroxytryptamine (fig. 1), none of them
was capable of inducing platelet aggregation, even at
a high concentration as 100 μηιοΐ/ΐ. In addition, we
reconfirmed that these heterocyclic amines did not
affect the first wave ADP-induced aggregation, as
reported previously (7).
Effects of heterocyclic amines on
5-hydroxytryptamine uptake by human
platelets
We also examined the effect of heterocyclic amines
on 5-hydroxytryptamine uptake by platelets, not only
because the carcinogenic heterocyclic amines struc-
turally resemble 5-hydroxytryptamine (fig. 1), but also
because some of the heterocyclic amines examined in
this study had potent inhibitory effects on the platelet
aggregation response to 5-hydroxytryptamine. In the
present system, the Km for 5-hydroxytryptamine up-
take was 1.6-2.2 μιηοΐ/ΐ (1.8 ± 0.25 μιηοΐ/ΐ, mean
± S. D., n = 4) with a Fmax of 16.5 pmol/5 min per
107 platelets. These results are slightly higher than
those reported previously (11, 16). This may be due
to differences in the anticoagulant used, the extraction
procedure for radioactive 5-hydroxytryptamine, or
the dilution medium used for the platelet-rich plasma.
It was confirmed by kinetic analysis that the inhibition
by 3-amino-l,4-dimethyl-5H-pyrido[4,3-b]indole is
competitive with 5-hydroxytryptamine, with a K{
value of 18 μιηοΐ/ΐ. Other heterocyclic amines such as
3-amino-l-methyl-5H-pyrido[4,3-b]indole, tetrahy-
dro- -carboline and harmine were less potent inhibi-
tors than 3-amino-l ,4-dimethyl-5H-pyrido[4,3-b]-
indole. The K{ values are summarized in table 2;
3-amino-l,4-dimethyl-5H-pyrido[4,3-b]indole is the
most potent inhibitor among the heterocyclic amines
studied.
Tab. 2. Effects of heterocyelic amines on platelet 5-hydroxy-
tryptamine uptake.
Compounds Km Uptake Type of(μιηοΙ/1) Κ\ Inhibition
(μιηοΐ/ΐ)
5-Hydroxytryptamine 1.8
Carcinogenic
heterocyclic amines
3-Amino-l,4-dimethyl- —
5KUpyndo[4,3-b]indole
3-Amino-l-methyl-5H- —
pyrido[4,3-b]indole
2-Amino-6-methyl-dipyrido —
[l,2-a:3',2'-d]imidazole
2-Aminodipyrido —
[l,2-a:3',2'-d]imidazole
2-Aminp-3-methyl- --
imidazo[4,5-f]quinoline
2-Aminp-3,8-dimethyl- —
imidazo[455-f]quinoxaline
-Carbolines
Tetrahydro- -carboline —
Norharman —
Harman —
Harmine —
• r
18
42
—
—
—
—
55
90
95
72
competitive
competitive
No inhibition
(100)*
No inhibition
(100)*
No inhibition
(100)*
No inhibition
(100)*
competitive
competitive
competitive
competitive
* The maximum concentration (μηιοΐ/ΐ) used for the experi-
ment.
Effects of heterocyclic amines on monoamine
oxidase
Monoamine oxidase is now classified into two types,
monoamine oxidase-A and -B, according to their sen-
sitivity to the specific inhibitors and their substrate
specificities. -Carbolines such as harmine and har-
man as well as other structural analogues of the
barman series are known to be reversible and com-
petitive inhibitors of monoamine oxidase-A (10 — 13).
Human platelets have been shown to contain almost
exclusively the B type, whereas human placenta con-
tains only the A type (18, 19). Therefore, human
placenta was used as a source of pure monoamine
oxidase-A and human platelets as a source of mono-
amine oxidase-B. Using the monoamine oxidase-A-
selective substrate, 5-hydroxytryptamine, and the
monoamine oxidase-B-selective substrate, phenyleth-
ylamine, the IC50 values were determined for the in-
hibition of monoamine oxidase-A and -B. Figure 3
shows the inhibition by heterocyclic amines of the
monoamine oxidase-A activity of human placenta
homogenate towards 10.4 μιηοΐ/ΐ 5-hydroxytrypt-
amine. The curves obtained with the heterocyclic
amines indicate the 3-amino-l,4-dimethyl-5H-pyr-
ido[4,3-b]indole and 3-amino-l-methyl^SH-pyr-
ido[4,3-b]indole, tryptophan pyrolysis products, were
more potent monoamine oxidase-A inhibitors than
other carcinogenic heterocyclic ahiines including 2-
J. Clin. Chem. Clin. Biochem. / Vol. 26,1988 / No. 5
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Fig. 3. Inhibition of monoamine oxidase A activities in human
placenta homogenate, using 10.4 μιηοΐ/l 5-hydroxy-
tryptamine, by carcinogenic heterocyclic amines and β-
carbolines.
ο —ο = harmine
Ο ο = 3-amino-l,4-dimethyl-5H-
pyrido[4,3-b]indole
ο ο = 3-amino-l-methyl-5H-
pyrido[4,3-b]indole
ο—ο = barman
ο ο — norharman
ο ο = tetrahydro- -carboline
Δ — Δ = 2-amino-6-methyldipyr-
ido[l92-a:3'92'-d]imidazoleΔ Δ = 2-anainodipyrido[l ,2-a:3',2'-d]imidazole
Δ Δ = 2-amino-3,8-dimethylimi-
dazo[4,5-f]quinoxaline
Δ Δ = 2-amino-3-methylimida-
zo[4,5-f]quinoline
Tab. 3. Effects of heterocyclic amines on human placenta and
platelet monoamine oxidase (MAO) activities.
Heterocyclic Amines ICso* (μηιοΐ/ΐ)
Carcinogenic
heterocyclic amines
3-Amino-1,4-dimethyl-
5H-pyrido[4,3-b]indole
3-Amino-l -methyl-5H-
pyrido[4,3-b]indole
2-Amino-6-methyldipyrido
[l,2-a:3',2'-d]imidazole
2-Aminodipyrido
[l,2-a:3',2'-d]imidazole
2-Anuno-3^methyl··
imidazo[4,5-f]quinoline
2-Amino-3,8-dimethyl-
imidazo[4,5rf]quinQxaline
5-Hydroxy- Phenyl-
tryptamine + ethylamine +
placenta MAO platelet MAO
0.45 > 200
0.70
>150
>150
>100
>100
>200
> 150
>150
>100
>100
-Carbolines
Tetrahydfo- -carboline
Norharman
Harman
Hannine
5.00
3.00
2.50
0:35
>150
70
80
60
* IC50 is the'concentration of heterocyclic amine required to
yield 50% inhibition of 10.4 jimol/1 5-hydroxytryptamine or
11.4 μηιοΐ/ΐ [14C]phenylethylamine deamination. Human pla-
centa was used as a source of monoamine oxidase-A and
human platelets as a source of monoamine oxidase-B.
amino-6-methyldipyrido[l,2-a:3^2'-d]imidazole, 2-
aminodipyrido[l,2-a:3',2'-d]imidazole, 2-amino-3-
methylimidazo[4,5-f|quinoline and 2-amino-3,8-di-
methylimidazo[4,5-f]quinoxaline. The IC50 values for
the inhibition of monoamine oxidase-A and -B were
summarized in table 3. The results shown in table 3
apparently indicate that 3-amino-l,4-dimethyl-5H-
pyrido[4,3-b]indole and 3-amino-l -methyl-5H-pyr-
ido[4,3-b]indole are selective monoamine oxidase-A
inhibitors.
Discussion
The results demonstrate that 3-amino-l,4-dimethyl-
5H-pyrido[4,3-b]indole and 3-amino-l -methyl-5H-
pyrido[4,3-b]indole, carcinogenic tryptophan pyro-
lysis products, have potent inhibitory effects on the
human platelet aggregation response to 5-hydroxy-
tryptamine, 5-hydroxytryptamine uptake by human
platelets and monoamine oxidase-A activities. Among
the carcinogenic heterocyclic amines studied in this
experiment, 3-amino-l ,4-dimethyl-5H-pyrido[4,3-b]-
indole and 3-amino-l-methyl-5H-pyrido[4,3-b]indole
showed greater pharmacological activities than other
carcinogenic heterocyclic amines such as 2-amino-6-
methyldipyridofl ,2-a:3',2'-d]imidazole, 2-aminodipyr-
ido[l,2-a:3/,2'-d]imidazole, 2-amino-3-methylimid-
azo[4,5-f]quinoline and 2-amino-3,8-dimethylimid-
azo[4,5-f]quinoxaline. This may be explained by the
fact that tryptophan pyrolysis products, like many
inhibitors of 5-hydroxytryptamine metabolism, are
related to 5-hydroxytryptamine (fig. 1). In this inves-
tigation, however, 3-amino-l ,4-dimethyl-5H-pyr-
ido[4,3-b]indole and 3-amino-l -methyl-5H-pyr-
ido[4,3-b]indole had more potent inhibitory effects on
5-hydroxytryptamine-induced platelet aggregation
and platelet 5-hydroxytryptamine uptake than -car-
bolines, which structurally resemble 5-hydroxytrypt-
amine (fig. 1, tab. 1 and 2). The reason was not clear,
but an amino-group of 3-amino-l ,4-dimethyl-5H-pyr-
ido[4,3-b]indole and 3-amino-l -methyl-5H-pyr-
ido[4,3-b]indole might play an important role in their
inhibitory actions on the platelet response to 5-hy-
droxytryptamine (fig. 1). On the other hand, -car-
bolines such as tetrahydro- -carboline, harman and
harmine as well as other structural analogues of har-
man series are known to be reversible and competitive
inhibitors of monoamine oxidase-A (10 — 13). In this
study, we reconfirmed that -carbolines were selective
monoamine oxidase-A inhibitors. Moreover, we
found that 3-amino-l,4-dimethyl-5H-pyrido[4,3-
b]indole, 3-amino-l-methyl-5H-pyrido[4,3-b]indole,
and γ-carbolines were also potent inhibitors of mono-
amine oxidase-A (fig. 3 and tab. 3). The results
J. Clin. Chem. Cljn, Biochem. / Vol. 26,1988 / No. 5
270 Manabe el ah: -Carbolines and monoamine metabolism
showed that 3-amino-l ,4-dimethyl-5H-pyrido-
[4,3-b]indole and 3-amino-l -methyl-5H-
pyrido[4,3-b]indole were more potent inhibitors of
monoamine oxidase-A than ß-carbolines, with the
exception of harmine. However, we could not provide
a satisfactory explanation for the observation that
harmine was the most potent inhibitor of monoamine
oxidase-A in the heterocyclic amines studied (tab. 3).
From the viewpoint of the chemical structures, further
studies are needed.
Recently, various carcinogenic heterocyclic amines
including 3-amino-l,4-dimethyl-5H-pyrido[4,3-b]-
indole, 3-amino-l-methyl-5H-pyrido[4,3-b]indole, 2-
amino-o-methyldipyridotl^-a^'^'-djimidazole and
2-aminodipyrido[l,2-a:3',2/-d]imidazole were identi-
fied in the dialysis fluid of uraemic patients and in
human plasma (3—6). The mean absolute amounts
of 3-amino-l,4-dimethyl-5H-pyrido[4,3-b]indole and
3-amino-l-methyl-5H-pyrido[4,3-b]indole in the di-
alysis fluid (6 -liters) were 727 pmol and 206 pmol,
respectively (4). The concentrations of the carcino-
genic heterocyclic amines in human plasma seem to
be well below those causing significant effects on the
platelet response to 5-hydroxytryptamine or on
monoamine oxidase activities. However, as mentioned
in our previous report (7), many factors, such as the
in vivo tissue distribution and accumulation of 3-
amino-1,4-dimethyl-5H-pyfido[4,3-b]indole and 3-
amino-l-methyl-5H-pyrido[4,3-b]itfdole, remain to be
investigated before the potential of tryptophan pyr-
olysis products for affecting cells such as platelets in
vivo can be determined.
In conclusion, 3-amino-l ,4-dimethyl-5H-pyr-
ido[4,3-b]indole and 3-amino-l -methyl-5H-
pyrido[4,3-b]indole, carcinogenic tryptophan pyroly-
sates, are potent inhibitors of the platelet aggregation
response to 5-hydroxytryptamine, 5-hydroxytrypt-
amine uptake by platelets and monoamine oxidase-A
activity.
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